Proliferative Vitreoretinopathy: A Review.
Idrees S, Sridhar J, Kuriyan AE.
Int Ophthalmol Clin. 2019 Winter;59(1):221-240. doi: 10.1097/IIO.0000000000000258.
Proliferative vitreoretinopathy.
Claes C, Lafetá AP.
Dev Ophthalmol. 2014;54:188-95. doi: 10.1159/000360466. Epub 2014 Aug 26.
Molecular Targets for Proliferative Vitreoretinopathy.
Wu F, Eliott D.
Semin Ophthalmol. 2021 May 19;36(4):218-223. doi: 10.1080/08820538.2021.1890791. Epub 2021 Feb 22.
Proliferative Vitreoretinopathy Following Transscleral Diode Cyclophotocoagulation.
Bai A, Sharma A, Chiang MY.
J Glaucoma. 2023 Jun 1;32(6):e66-e68. doi: 10.1097/IJG.0000000000002222. Epub 2023 Mar 30.
Proliferative vitreoretinopathy: an update on the current and emerging treatment options.
Ferro Desideri L, Artemiev D, Zandi S, Zinkernagel MS, Anguita R.
Graefes Arch Clin Exp Ophthalmol. 2024 Mar;262(3):679-687. doi: 10.1007/s00417-023-06264-1. Epub 2023 Oct 16.
Proliferative vitreoretinopathy.
Leaver PK.
Br J Ophthalmol. 1995 Oct;79(10):871-2. doi: 10.1136/bjo.79.10.871.
[Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].
Schaub F, Abdullatif AM, Fauser S.
Ophthalmologe. 2021 Jan;118(1):3-9. doi: 10.1007/s00347-020-01173-8.
In vitro laboratory models of proliferative vitreoretinopathy.
Gao AY, Haak AJ, Bakri SJ.
Surv Ophthalmol. 2023 Sep-Oct;68(5):861-874. doi: 10.1016/j.survophthal.2023.05.007. Epub 2023 May 19.
[Proliferative vitreoretinopathy: the unsolved problem].
Grisanti S.
Ophthalmologe. 2021 Jan;118(1):2. doi: 10.1007/s00347-020-01295-z.
TSPAN4-positive migrasome derived from retinal pigmented epithelium cells contributes to the development of proliferative vitreoretinopathy.
Wu L, Yang S, Li H, Zhang Y, Feng L, Zhang C, Wei J, Gu X, Xu G, Wang Z, Wang F.
J Nanobiotechnology. 2022 Dec 9;20(1):519. doi: 10.1186/s12951-022-01732-y.
